Abbott to Report Q3 Earnings: Medical Devices Arm in Focus

Core Insights - Abbott Laboratories (ABT) is set to report its third-quarter 2025 results on October 15, with adjusted earnings per share (EPS) of $1.26 in the last quarter, exceeding the Zacks Consensus Estimate by 0.8% [1][8] Revenue and EPS Estimates - The Zacks Consensus Estimate for Q3 revenues is $11.42 billion, reflecting a 7.4% increase from the previous year [2][8] - The Zacks Consensus Estimate for EPS is $1.30, indicating a 7.4% improvement from the prior year's figure [2][8] Segment Performance Expectations - Diagnostics: Revenue growth is expected to be impacted by a decline in COVID-19 testing revenues and volume-based procurement programs in China, with a projected decrease of 4.4% year over year [3][4] - Established Pharmaceuticals (EPD): Strong performance is anticipated across key markets, with a year-over-year revenue increase of 9%, driven by biosimilars as a new growth pillar [5][6] - Medical Devices: Expected growth of 13.3% year over year, supported by the Diabetes Care division and the integration of Libre CGM data into Epic's EHR systems [6][11] - Nutrition: Anticipated revenue growth of 6.3% year over year, driven by strong sales of adult nutrition brands like Ensure and Glucerna [12] Recent Developments - Abbott's Structural Heart segment is expected to see growth from surgical valves and transcatheter products, bolstered by recent CE Mark and FDA approvals [9][11] - The Rhythm Management arm is gaining traction with the leadless AVEIR pacemaker, supported by favorable clinical data [10] Earnings ESP and Zacks Rank - Abbott has an Earnings ESP of 0.00% and currently holds a Zacks Rank of 3, indicating a neutral outlook for beating estimates [13]